{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T03:55:18Z","timestamp":1788926118407,"version":"build-2803163510"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2014,12,12]],"date-time":"2014-12-12T00:00:00Z","timestamp":1418342400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2014,12,12]],"date-time":"2014-12-12T00:00:00Z","timestamp":1418342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer Journal"],"DOI":"10.1038\/bcj.2014.84","type":"journal-article","created":{"date-parts":[[2014,12,12]],"date-time":"2014-12-12T14:15:46Z","timestamp":1418393746000},"page":"e268-e268","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Definition and management of ruxolitinib treatment failure in myelofibrosis"],"prefix":"10.1038","volume":"4","author":[{"given":"A","family":"Pardanani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Tefferi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,12,12]]},"reference":[{"key":"BFbcj201484_CR1","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/nature03546","volume":"434","author":"C James","year":"2005","unstructured":"James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144\u20131148.","journal-title":"Nature"},{"key":"BFbcj201484_CR2","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","volume":"108","author":"AD Pardanani","year":"2006","unstructured":"Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006; 108: 3472\u20133476.","journal-title":"Blood"},{"key":"BFbcj201484_CR3","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","volume":"3","author":"Y Pikman","year":"2006","unstructured":"Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006; 3: e270.","journal-title":"PLoS Med"},{"key":"BFbcj201484_CR4","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","volume":"124","author":"A Tefferi","year":"2014","unstructured":"Tefferi A, Guglielmelli P, Larson DR, Finke C, Wassie EA, Pieri L et al. Long-term survival and blast transformation in molecularly-annotated essential thrombocythemia, polycythemia vera and myelofibrosis. Blood 2014; 124: 2507\u20132513.","journal-title":"Blood"},{"key":"BFbcj201484_CR5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.mayocp.2011.11.001","volume":"87","author":"A Tefferi","year":"2012","unstructured":"Tefferi A, Lasho TL, Jimma T, Finke CM, Gangat N, Vaidya R et al. One thousand patients with primary myelofibrosis: the mayo clinic experience. Mayo Clin Proc 2012; 87: 25\u201333.","journal-title":"Mayo Clin Proc"},{"key":"BFbcj201484_CR6","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","volume":"29","author":"N Gangat","year":"2011","unstructured":"Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011; 29: 392\u2013397.","journal-title":"J Clin Oncol"},{"key":"BFbcj201484_CR7","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1038\/leu.2014.76","volume":"28","author":"P Guglielmelli","year":"2014","unstructured":"Guglielmelli P, Lasho TL, Rotunno G, Score J, Mannarelli C, Pancrazzi A et al. The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. Leukemia 2014; 28: 1804\u20131810.","journal-title":"Leukemia"},{"key":"BFbcj201484_CR8","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1038\/leu.2014.57","volume":"28","author":"A Tefferi","year":"2014","unstructured":"Tefferi A, Guglielmelli P, Lasho TL, Rotunno G, Finke C, Mannarelli C et al. CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients. Leukemia 2014; 28: 1494\u20131500.","journal-title":"Leukemia"},{"key":"BFbcj201484_CR9","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1038\/bcj.2011.4","volume":"1","author":"A Tefferi","year":"2011","unstructured":"Tefferi A, Abdel-Wahab O, Cervantes F, Crispino JD, Finazzi G, Girodon F et al. Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium. Blood Cancer J 2011; 1: e7.","journal-title":"Blood Cancer J"},{"key":"BFbcj201484_CR10","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1002\/ajh.23703","volume":"89","author":"A Tefferi","year":"2014","unstructured":"Tefferi A . Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol 2014; 89: 915\u2013925.","journal-title":"Am J Hematol"},{"key":"BFbcj201484_CR11","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1038\/bcj.2012.3","volume":"2","author":"K Ballen","year":"2012","unstructured":"Ballen K . How to manage the transplant question in myelofibrosis. Blood Cancer J 2012; 2: e59.","journal-title":"Blood Cancer J"},{"key":"BFbcj201484_CR12","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","volume":"363","author":"S Verstovsek","year":"2010","unstructured":"Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010; 363: 1117\u20131127.","journal-title":"N Engl J Med"},{"key":"BFbcj201484_CR13","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012; 366: 799\u2013807.","journal-title":"N Engl J Med"},{"key":"BFbcj201484_CR14","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/NEJMoa1110556","volume":"366","author":"C Harrison","year":"2012","unstructured":"Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012; 366: 787\u2013798.","journal-title":"N Engl J Med"},{"key":"BFbcj201484_CR15","unstructured":"Jakafi (Ruxolitinib) label.http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/202192lbl.pdf."},{"key":"BFbcj201484_CR16","doi-asserted-by":"publisher","first-page":"4047","DOI":"10.1182\/blood-2013-02-485888","volume":"122","author":"F Cervantes","year":"2013","unstructured":"Cervantes F, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Sirulnik A, Stalbovskaya V et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood 2013; 122: 4047\u20134053.","journal-title":"Blood"},{"key":"BFbcj201484_CR17","doi-asserted-by":"crossref","unstructured":"Verstovsek S, Mesa R, Gotlib J, Levy R, Gupta V, DiPersio J et al. Long-term outcomes of ruxolitinib therapy in patients with myelofibrosis: 3-year update from COMFORT-I. Blood 2013; 122, abstract 396.","DOI":"10.1182\/blood.V122.21.396.396"},{"key":"BFbcj201484_CR18","doi-asserted-by":"crossref","unstructured":"Fonseca E, Silver RT, Kazis L, Usman Iqbal S, Rose M, Khan N et al. Ruxolitinib discontinuation in patients with myelofibrosis: an analysis from clinical practice. Blood 2013; 122, abstract 2833.","DOI":"10.1182\/blood.V122.21.2833.2833"},{"key":"BFbcj201484_CR19","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1056\/NEJMc1109555","volume":"365","author":"A Tefferi","year":"2011","unstructured":"Tefferi A, Litzow MR, Pardanani A . Long-term outcome of treatment with ruxolitinib in myelofibrosis. N Engl J Med 2011; 365: 1455\u20131457.","journal-title":"N Engl J Med"},{"key":"BFbcj201484_CR20","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1182\/blood-2012-02-414631","volume":"120","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Kantarjian HM, Estrov Z, Cortes JE, Thomas DA, Kadia T et al. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1\/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood 2012; 120: 1202\u20131209.","journal-title":"Blood"},{"key":"BFbcj201484_CR21","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1111\/bjh.12948","volume":"167","author":"M Kremyanskaya","year":"2014","unstructured":"Kremyanskaya M, Mascarenhas J, Rampal R, Hoffman R . Development of extramedullary sites of leukaemia during ruxolitinib therapy for myelofibrosis. Br J Haematol 2014; 167: 144\u2013146.","journal-title":"Br J Haematol"},{"key":"BFbcj201484_CR22","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.4065\/mcp.2011.0518","volume":"86","author":"A Tefferi","year":"2011","unstructured":"Tefferi A, Pardanani A . Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. Mayo Clin Proc 2011; 86: 1188\u20131191.","journal-title":"Mayo Clin Proc"},{"key":"BFbcj201484_CR23","doi-asserted-by":"publisher","first-page":"e430","DOI":"10.1200\/JCO.2012.47.6473","volume":"31","author":"T Dai","year":"2013","unstructured":"Dai T, Friedman EW, Barta SK . Ruxolitinib withdrawal syndrome leading to tumor lysis. J Clin Oncol 2013; 31: e430\u2013e432.","journal-title":"J Clin Oncol"},{"key":"BFbcj201484_CR24","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1007\/s12185-014-1628-5","volume":"100","author":"Y Beauverd","year":"2014","unstructured":"Beauverd Y, Samii K . Acute respiratory distress syndrome in a patient with primary myelofibrosis after ruxolitinib treatment discontinuation. Int J Hematol 2014; 100: 498\u2013501.","journal-title":"Int J Hematol"},{"key":"BFbcj201484_CR25","doi-asserted-by":"crossref","unstructured":"Robin M, Francois S, Huynh A, Cassinat B, Bay J-O, Cornillon J et al. Ruxolitinib before allogeneic hematopoietic stem cell transplantation (HSCT) in patients with myelofibrosis: a preliminary descriptive report of the JAK ALLO study, a phase II trial sponsored By Goelams-FIM in collaboration With The Sfgmtc. Blood 2013; 122, abstract 306.","DOI":"10.1182\/blood.V122.21.306.306"},{"key":"BFbcj201484_CR26","doi-asserted-by":"crossref","unstructured":"Kroger N, Alchalby H, Ditschkowski M, Wolf D, Wulf G, Zabelina T et al. Ruxolitinib as pretreatment before allogeneic stem cell transplantation for myelofibrosis. Blood 2013; 122, abstract 392.","DOI":"10.1182\/blood.V122.21.392.392"},{"key":"BFbcj201484_CR27","doi-asserted-by":"crossref","unstructured":"Lebon D, Rubio M, Legrand F, Kiladjian J-J, Mohty M, Cahn J-Y et al. Ruxolitinib for patients with primary or secondary myelofibrosis before allogeneic hematopoietic stem cell transplantation (allo-HSCT): a retrospective study of the Soci\u00e9t\u00e9 Fran\u00e7aise De Greffe De Moelle Et De Th\u00e9rapie Cellulaire (SFGM-TC). Blood 2013; 122, abstract 2111.","DOI":"10.1182\/blood.V122.21.2111.2111"},{"key":"BFbcj201484_CR28","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1038\/leu.2014.220","volume":"28","author":"G Barosi","year":"2014","unstructured":"Barosi G, Zhang MJ, Peter Gale R . Does ruxolitinib improve survival of persons with MPN-associated myelofibrosis? Should it? Leukemia 2014; 28: 2267\u20132270.","journal-title":"Leukemia"},{"key":"BFbcj201484_CR29","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.leukres.2014.06.012","volume":"38","author":"RP Gale","year":"2014","unstructured":"Gale RP, Barosi G . Commentary. Leukemia Res 2014; 38: 1013\u20131015.","journal-title":"Leukemia Res"},{"key":"BFbcj201484_CR30","doi-asserted-by":"crossref","unstructured":"Harrison C, Schaap N, Zweegman S, Jourdan E, Kiladjian J, Cervantes F et al. Efficacy and safety of Fedratinib (SAR302503\/TG101348) in patients with intermediate- or high-risk myelofibrosis (MF), post-polycythemia vera (PV) MF, or post-essential thrombocythemia (ET) MF previously treated with Ruxolitinib: interim results from a phase II tudy (JAKARTA-2). Blood 2013; 122: abstract 661.","DOI":"10.1182\/blood.V122.21.661.661"},{"key":"BFbcj201484_CR31","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3109\/10428194.2013.794269","volume":"55","author":"FP Santos","year":"2014","unstructured":"Santos FP, Tam CS, Kantarjian H, Cortes J, Thomas D, Pollock R et al. Splenectomy in patients with myeloproliferative neoplasms: efficacy, complications and impact on survival and transformation. Leuk Lymphoma 2014; 55: 121\u2013127.","journal-title":"Leuk Lymphoma"},{"key":"BFbcj201484_CR32","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/cncr.22021","volume":"107","author":"RA Mesa","year":"2006","unstructured":"Mesa RA, Nagorney DS, Schwager S, Allred J, Tefferi A . Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. Cancer 2006; 107: 361\u2013370.","journal-title":"Cancer"},{"key":"BFbcj201484_CR33","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1182\/blood.V95.7.2226","volume":"95","author":"A Tefferi","year":"2000","unstructured":"Tefferi A, Mesa RA, Nagorney DM, Schroeder G, Silverstein MN . Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood 2000; 95: 2226\u20132233.","journal-title":"Blood"},{"key":"BFbcj201484_CR34","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1038\/bcj.2011.36","volume":"1","author":"F Cervantes","year":"2011","unstructured":"Cervantes F . How I treat splenomegaly in myelofibrosis. Blood Cancer J 2011; 1: e37.","journal-title":"Blood Cancer J"},{"key":"BFbcj201484_CR35","doi-asserted-by":"crossref","unstructured":"McMullin MF, Harrison C, Niederwieser D, Demuynck H, Jakel N, Sirulnik A et al. The use of erythropoietic-stimulating agents (ESAs) with ruxolitinib in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), and post-essential thrombocythemia myelofibrosis (PET-MF). Blood 2012; 120, abstract 2838.","DOI":"10.1182\/blood.V120.21.2838.2838"},{"issue":"5","key":"BFbcj201484_CR36","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1200\/JCO.2013.51.0057","volume":"34","author":"Michael R. Grunwald","year":"2016","unstructured":"Grunwald MR, Spivak JL . Ruxolitinib enhances platelet production in patients with thrombocytopenic myelofibrosis. J Clin Oncol 2014, e-pub ahead of print 23 June 2014; doi:10.1200\/JCO.2013.51.0057.","journal-title":"Journal of Clinical Oncology"},{"key":"BFbcj201484_CR37","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/ajh.21799","volume":"85","author":"A Pardanani","year":"2010","unstructured":"Pardanani A, Brown P, Neben-Wittich M, Tobin R, Tefferi A . Effective management of accelerated phase myelofibrosis with low-dose splenic radiotherapy. Am J Hematol 2010; 85: 715\u2013716.","journal-title":"Am J Hematol"},{"key":"BFbcj201484_CR38","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1038\/leu.2008.91","volume":"22","author":"A Quintas-Cardama","year":"2008","unstructured":"Quintas-Cardama A, Tong W, Kantarjian H, Thomas D, Ravandi F, Kornblau S et al. A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia\/polycythemia vera myelofibrosis. Leukemia 2008; 22: 965\u2013970.","journal-title":"Leukemia"},{"key":"BFbcj201484_CR39","doi-asserted-by":"publisher","first-page":"447","DOI":"10.3109\/10428194.2013.802315","volume":"55","author":"Y Liu","year":"2014","unstructured":"Liu Y, Tabarroki A, Billings S, Visconte V, Rogers HJ, Hasrouni E et al. Successful use of very low dose subcutaneous decitabine to treat high-risk myelofibrosis with Sweet syndrome that was refractory to 5-azacitidine. Leuk Lymphoma 2014; 55: 447\u2013449.","journal-title":"Leuk Lymphoma"},{"key":"BFbcj201484_CR40","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1111\/j.1365-2141.2008.07541.x","volume":"145","author":"AV Danilov","year":"2009","unstructured":"Danilov AV, Relias V, Feeney DM, Miller KB . Decitabine is an effective treatment of idiopathic myelofibrosis. Br J Haematol 2009; 145: 131\u2013132.","journal-title":"Br J Haematol"},{"key":"BFbcj201484_CR41","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/leu.2008.136","volume":"23","author":"RA Mesa","year":"2009","unstructured":"Mesa RA, Verstovsek S, Rivera C, Pardanani A, Hussein K, Lasho T et al. 5-Azacitidine has limited therapeutic activity in myelofibrosis. Leukemia 2009; 23: 180\u2013182.","journal-title":"Leukemia"},{"key":"BFbcj201484_CR42","doi-asserted-by":"crossref","unstructured":"Odenike O, Godwin J, Van Besien K, Huo D, Sher D, Burke P et al. Phase II trial of low dose, subcutaneous decitabine in myelofibrosis. Blood 2008; 112, abstract 2809.","DOI":"10.1182\/blood.V112.11.2809.2809"},{"key":"BFbcj201484_CR43","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1182\/blood-2013-03-484642","volume":"122","author":"A Heine","year":"2013","unstructured":"Heine A, Held SA, Daecke SN, Wallner S, Yajnanarayana SP, Kurts C et al. The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood 2013; 122: 1192\u20131202.","journal-title":"Blood"},{"key":"BFbcj201484_CR44","doi-asserted-by":"publisher","first-page":"3843","DOI":"10.1182\/blood-2013-10-531103","volume":"122","author":"A Heine","year":"2013","unstructured":"Heine A, Brossart P, Wolf D . Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis? Blood 2013; 122: 3843\u20133844.","journal-title":"Blood"},{"key":"BFbcj201484_CR45","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1378\/chest.12-1604","volume":"143","author":"NG Wysham","year":"2013","unstructured":"Wysham NG, Sullivan DR, Allada G . An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor. Chest 2013; 143: 1478\u20131479.","journal-title":"Chest"},{"issue":"jun02 1","key":"BFbcj201484_CR46","first-page":"bcr2014204950","volume":"2014","author":"S. C. Lee","year":"2014","unstructured":"Lee SC, Feenstra J, Georghiou PR . Pneumocystis jiroveci pneumonitis complicating ruxolitinib therapy. BMJ Case Rep 2014, e-pub ahead of print 2 June 2014; doi:10.1136\/bcr-2014-204950.","journal-title":"Case Reports"},{"key":"BFbcj201484_CR47","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1056\/NEJMc1302895","volume":"369","author":"RA Goldberg","year":"2013","unstructured":"Goldberg RA, Reichel E, Oshry LJ . Bilateral toxoplasmosis retinitis associated with ruxolitinib. N Engl J Med 2013; 369: 681\u2013683.","journal-title":"N Engl J Med"},{"key":"BFbcj201484_CR48","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1186\/1756-0500-5-552","volume":"5","author":"C Colomba","year":"2012","unstructured":"Colomba C, Rubino R, Siracusa L, Lalicata F, Trizzino M, Titone L et al. Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report. BMC Res Notes 2012; 5: 552.","journal-title":"BMC Res Notes"},{"key":"BFbcj201484_CR49","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/leu.2013.235","volume":"28","author":"G Caocci","year":"2014","unstructured":"Caocci G, Murgia F, Podda L, Solinas A, Atzeni S, La Nasa G et al. Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis. Leukemia 2014; 28: 225\u2013227.","journal-title":"Leukemia"},{"key":"BFbcj201484_CR50","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1016\/j.jaad.2013.09.035","volume":"70","author":"LX Tong","year":"2014","unstructured":"Tong LX, Jackson J, Kerstetter J, Worswick SD . Reactivation of herpes simplex virus infection in a patient undergoing ruxolitinib treatment. J Am Acad Dermatol 2014; 70: e59\u2013e60.","journal-title":"J Am Acad Dermatol"},{"key":"BFbcj201484_CR51","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1056\/NEJMc1302135","volume":"369","author":"R Wathes","year":"2013","unstructured":"Wathes R, Moule S, Milojkovic D . Progressive multifocal leukoencephalopathy associated with ruxolitinib. N Engl J Med 2013; 369: 197\u2013198.","journal-title":"N Engl J Med"},{"key":"BFbcj201484_CR52","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1038\/leu.2011.374","volume":"26","author":"A Tefferi","year":"2012","unstructured":"Tefferi A, Pardanani A, Gangat N, Begna KH, Hanson CA, Van Dyke DL et al. Leukemia risk models in primary myelofibrosis: an International Working Group study. Leukemia 2012; 26: 1439\u20131441.","journal-title":"Leukemia"},{"key":"BFbcj201484_CR53","doi-asserted-by":"publisher","first-page":"4595","DOI":"10.1182\/blood-2011-08-371096","volume":"118","author":"A Tefferi","year":"2011","unstructured":"Tefferi A, Jimma T, Gangat N, Vaidya R, Begna KH, Hanson CA et al. Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically annotated patients. Blood 2011; 118: 4595\u20134598.","journal-title":"Blood"},{"key":"BFbcj201484_CR54","doi-asserted-by":"publisher","first-page":"4614","DOI":"10.1182\/blood-2011-12-400051","volume":"119","author":"A Eghtedar","year":"2012","unstructured":"Eghtedar A, Verstovsek S, Estrov Z, Burger J, Cortes J, Bivins C et al. Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia. Blood 2012; 119: 4614\u20134618.","journal-title":"Blood"},{"key":"BFbcj201484_CR55","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1182\/blood-2013-03-488098","volume":"122","author":"A Tefferi","year":"2013","unstructured":"Tefferi A, Cervantes F, Mesa R, Passamonti F, Verstovsek S, Vannucchi AM et al. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood 2013; 122: 1395\u20131398.","journal-title":"Blood"},{"issue":"1","key":"BFbcj201484_CR56","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/leu.2014.250","volume":"29","author":"G Barosi","year":"2014","unstructured":"Barosi G, Tefferi A, Besses C, Birgegard G, Cervantes F, Finazzi G et al. Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements froim European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT). Leukemia 2014, e-pub ahead of print 25 August 2014; doi:10.1038\/leu.2014.250.","journal-title":"Leukemia"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bcj201484.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201484","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201484.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T22:54:52Z","timestamp":1672959292000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bcj201484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,12]]},"references-count":56,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2014,12]]}},"alternative-id":["BFbcj201484"],"URL":"https:\/\/doi.org\/10.1038\/bcj.2014.84","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,12]]},"assertion":[{"value":"4 October 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AT was Principal Investigator for Phase-1\/2 ruxolitinib study (NCT00509899) in myelofibrosis for the Mayo Clinic (Rochester) site. The sponsor (Incyte) funded the clinical trial and provided study drug, but was not involved in any way in the current manuscript. AP and AT are\/have served as Principal Investigators for other clinical trials for myelofibrosis treatment with JAK inhibitors and other agents.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}